Coronavirus (COVID-19) Statement

We continue to closely monitor the situation surrounding the COVID-19 pandemic and are following the published recommendations of the CDC and the American Academy of Ophthalmology. We will continue to see our patients and treat any urgent/emergent needs.

With all of our offices open, the following protocols are in place:

1) We have greatly expanded measures to disinfect our office including cleaning between each patient appointment.

2) To limit any potential exposure, we ask you NOT to bring any non-essential person(s) with you to the appointment.

3) If someone must accompany you to your appointment, we ask that they do not enter the office, if at all possible.

4) If you have an upcoming appointment and identify with the following statements, please do not come directly to the office, but instead call us:

• Fever greater than 100.4

• Respiratory symptoms or difficulty breathing

• Exposed to someone with COVID-19 in the past 14 days

• Placed in self/hospital quarantine by medical doctor

 Your health and that of our staff is our guiding priority and we continue to update our protocol to ensure safety for everyone. If you have questions regarding these evolving protocols, please contact our office.


Ivan R. Batlle, M.D.


  • Ivan R. Batlle, M.D.


  • February 7, 1960; Dominican Republic


April 2009 - PRESENT:

  • Retina Associates, P.A.
    Santa Fe Medical Building
    9301 West 74th Street
    Suite 210
    Shawnee Mission, KS 66204
  • Retina Associates, P.A.
    6201 College Boulevard
    Suite 200
    Overland Park, KS 66211
  • Retina Associates. P.A.
    10100 N Ambassador Drive
    Suite 100
    Kansas City, MO 64153
  • Retina Associates, P.A.
    6001 SW 6th Avenue
    Suite 300
    Topeka, KS 66615
  • Retina Associates, P.A.
    3700 W 10th Street
    Suite 101
    Sedalia, MO 65301
  • Retina Associates, P.A.
    100 NE Missouri Road
    Suite 203
    Lee's Summit, MO 64086

June 2008 – April 2009:

  • South Texas Retina Consultants, LLP Corpus Christi, TX

2006 – May 2008:

  • Mid-America Retina Consultants, P.A. Kansas City, MO

2004 – 2005:

  • East Jefferson Hospital
    Metairie, LA
    Chairman Department of Ophthalmology
  • Touro Infirmary
    New Orleans, LA
    Chairman Department of Ophthalmology
  • Homesite Medical Director

1999 – December 2005:

  • Retina Associates New Orleans, LA

1997 – 1999:

  • President of Oftalmologia Especializada, A.P.C.
    Santo Domingo, Dominican Republic
  • La Asociacion La Hora de Dios
    Santo Domingo, Dominican Republic
    Director of Ophthalmology

1996 – 1999:

  • President Consultorio Oftalmologico Ozama, A.P.C. Santo Domingo, Dominican Republic

1992 – 1998:

  • Universidad de Puerto Rico Dept. of Ophthalmology
    San Juan, Puerto Rico
    Instructor Basic Sciences Course

1991 – 1996:

  • Vice-President Centro de Microcirugia Ocular y Laser Santo Domingo, Dominican Republic

1990 – 1991:

  • Gitter and Cohen Associate New Orleans, LA


  • FELLOWSHIP: Medical/Surgical Retina – Touro Infirmary/The Foundation for Retinal Research, 1401 Foucher Street, New Orleans, LA 70115 (July 1, 1986 – June 30, 1990) Fellowship Director: Kurt A. Gitter, M.D.
  • RESIDENCY: Ophthalmology – Bascom Palmer Eye Institute, University of Miami School of Medicine, 900 NW 17th Street, Miami, FL 33136 (July 1, 1986 – June 30, 1989)
  • INTERNSHIP: Medicine – The Alton Ochsner Medical Foundation, Ochsner Clinic, New Orleans E, 5701 Deer Park Blvd, New Orleans, LA 70127 (July 1, 1985 – June 30, 1986)
  • MEDICAL SCHOOL: Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112 (1981-1985)
  • UNDERGRADUATE: Vanderbilt University, 2201 West End Avenue, Nashville, TN 37235 (1977-1981)


  • Fellow American College of Surgeons
  • Fellow American Academy of Ophthalmology
  • American Medical Association
  • Pan-American Association of Ophthalmology
  • New Orleans Academy of Ophthalmology, Program Chairman 2004, Board Member 2004 – Present
  • American Society of Retina Specialists
  • Louisiana Ophthalmology Society
  • Sociedad Dominicana de Oftalmologia, President 1995-1996
  • Santo Domingo Rotary Club, President 1994-1995
  • Patronato Nacional de Ciegos, Vice-President 1995-1998


  • American Board of Ophthalmology 1990
  • Louisiana Board of Medical Examiners 1990 – Present
  • Mississippi Board of Medical Licensure 1999 – Present
  • Ministry of Health of the Dominican Republic 1991 – Present


  • Periocular Triamcinolone Acetonide as Treatment for Macular Edema Secondary to Branch Vein Occlusion Associated with Retinal Arteriovenous Malformation. Retina:26(9):1079-1080, November 2006
  • Ischemic and Hemorrhagic Retinal Vasculitis Associated with West Nile Virus Infection. Retina: 26(3):365-367, March 2006
  • Guest speaker Fundacion Oftalmologica Nacional, Bogota, Columbia 2005
  • Panelist Pan American Congress of Ophthalmology, Puerto Rico 2003
  • Panelist Pan American Congress of Ophthalmology, Chile 2005
  • Retinal Panel Joint Meeting of the American Academy of Ophthalmology/Pan American Association of Ophthalmology, 2002
  • Speakers Forum, Novartis Pharmaceuticals 2001-2005
  • Clinical and Electrophysiologic Findings in a Family of Homozygous Recessive RP Patients, Ophthalmology 2000
  • Functional and Anatomic Results in the Management of Retinal Detachment, Dominican Ophthalmological Society, 1996 Pan American Congress of Ophthalmology, Cancun, Mexico 1996
  • Vernal Incidence of Central Serous Choroidopathy, Dominican Ophthalmological Society 1995
  • Visual results of Scleral Fixation Intraocular Lenses, Dominican Ophthalmological Society 1994
  • The Surgical Results in the Management of Advanced Stages of Sickle-Cell Retinopathy, The Vitreous Society 1994
  • Vitamin A Enhancement of Cataract Wound Closure, Annals of Ophthalmology 1988


  • Alcon AART C-02-60: Anecortave Acetate Risk Reductions Trial for patients with Non-Neovascular, Investigator.
  • Alcon C-98-03: An Evaluation of Safety and Efficacy of Anecortave Acetate Sterile Suspension (30mg, 15mg, or 3mg) versus Placebo following Sub-Tenon Injections for the Inhibition of Neovascularization in patients with Exudative Age-Related Macular Degeneration, Sub-Investigator. 9/1999-11/2001
  • ISTA Pharmaceuticals Protocol Vit-02-0896XX
  • Miravant Medical Technologies/Pharmacia & Upjohn Protocol SnET5-98EA001
  • QLT Photos Therapeutics, Inc./Ciba Vision, Verteporfin in ARMD (V.A.M.) Study
  • Collaborative Ocular Melanoma Study (COMS)
  • AREDS2: A Multicenter, Randomized Trial to access the effects of oral supplementation of Macular Xanthophyllis (Lutein + ZEAXANTHIN) and or Long-Chain Omega-3 Fatty Acids 9DHA) and EPA on the Progression of Advanced Age-Related Macular Degeneration, Investigator.
  • National Eye Institute SCORE Study: Standard Care vs. Corticosteroid for Retinal Vein Occlusion, Sub-Investigator.
  • An Observational Study of the Development of Diabetic Macular Edema Following Scatter Laser Photocoagulation: Principal Investigator
  • Alimera Sciences: A Randomized, Double-Masked, Parallel Group, Multi-Center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 µg/day and ASI-001B 0.2 µg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema, Investigator.
  • Eyetech EOP1010: An Open-Label, Non-Comparative Protocol for the use of Pegaptanib Sodium injection every 6 weeks in patients with Exudative Age-Related Macular Degeneration, Sub-Investigator. 11/2004-11/2005
  • Eyetech EOP1011: A Phase III, Randomized, Dose-Ranging, Double-Masked, Multicenter Trial, in parallel groups to determine the Safety, Efficacy, and Pharmacokinetics of Intravitreal Injections of Pegaptanib Sodium compared to Sham Injections for 30 weeks in patients with recent vision loss due to Macular Edema Secondary to Central Retinal Vein Occlusion, Investigator. 9/2004-11/2006
  • Eyetech EOP1004: A Phase II/III, Randomized, Controlled, Double-Masked, Dose-Finding, Multicenter, Comparative Trial in Parallel Groups to establish the Safety and Efficacy of Intravitreal Injections of EYE001 (AntiVEGF Pegylated Aptamer) given every 6 weeks for patients with Exudative Age-Related Macular Degeneration, Sub-Investigator. 8/2001-11/2005
  • Genentech FVF3192g (PIER): A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection controlled Study of the Efficacy and Safety of Ranibizumab in patients with Subfoveal Choroidal Neovascularization with or without classic CNV secondary to age-related macular degeneration, Sub-Investigator.
  • Genentech FVF4165g (BRAVO): A Multicenter, Randomized, Double-Masked, Sham injection-controlled Phase III Study to assess the Safety and Efficacy of Ranibizumab for the treatment of Macular Edema secondary to Branch Retinal Vein Occlusion, Sub-Investigator.
  • Genentech FVF4166g (SHORE): A Multicenter, Randomized. Double-Masked, Sham-Injection Controlled Phase III Study to assess the Safety and Efficacy of Ranibizumab for the treatment of Macular Edema secondary to Central Retinal Vein Occlusion, Sub-Investigator.
  • Genentech FVF4168g (RIDE): A Phase III, Double-Masked, Multi-Center, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus, Sub-Investigator
  • Genentech FVF4579g (HARBOR): A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and safety of 0.5mg and 2.0mg Ranibizumab Administered monthly or on an As-Needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration, Sub-Investigator.
  • Genentech FVF4967g (SHORE): A Multicenter, Randomized Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion, Sub-Investigator.
  • VGFT-OD-0605: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration, Principal Investigator.
  • Oculex Pharmaceuticals DC 103-06-02: A Phase II, Randomized, Multicenter, Dose-Ranging, Controlled, Parallel Group Trial to assess the Safety and Efficacy of a posterior Segment Drug Delivery System in the treatment of persistent Macular Edema, Investigator. 10/2001-06/2003.
  • Ophthotech OPH1001: A Phase II, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-Peglayted Aptamer) given in combination with Lucentis in subjects with NVAMD, Sub-Investigator
  • Lux BioSciences LX211-11: A Multi-center, Double-Masked, Parallel Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Noninfectious Intermediate, Posterior or Pan-uveitis, Sub-Investigator.


  • “Update on the Treatment of Diabetic Retinopathy “

A Vision to be the Best

As the largest group of Retina specialists in the Greater Kansas City, Topeka, Sedalia and surrounding areas we offer multiple professional offices to serve you.  Each of our offices are staffed and equipped to provide the highest level of health care service and access in a comfortable environment.

Dr. Batlle is currently seeing patients at our Topeka, Shawnee Mission and Lee's Summit locations

Retina Associates, PA

Retina Associates, PA is an advanced medical practice devoted to the diagnosis and treatment of retinal, macular, and vitreous diseases. Together, our eye care physicians belong to various prestigious organizations: 

  • American Board of Ophthalmology
  • American Medical Association
  • American Academy of Ophthalmology
  • Association for Research in Vision and Ophthalmology
  • American College of Surgeons
  • American Society of Retina Specialists

Our mission is to help every patient preserve or restore their sight through our advanced treatment options. To discuss your needs with one of our doctors, request an appointment online or call us at (913) 831-7400.

Contact Us

Rate, Review & Explore

Social Accounts Sprite

Shawnee Mission Office

9301 W 74th St
Ste 210
Shawnee Mission, KS 66204

Open Today 8:00am - 5:00pm

What is the best time for you?

Add additional time

Tell us a bit about yourself...

(913) 831-7400 Send a message